Coronary angioplasty via radial access using 4 Fr introducer. Minimally invasive to the extreme.

Original title: Comparison of frequency of Radial Artery Oclusion Alter 4Fr Versus 6Fr Transradial Coronary intervention (from the Novel Angioplasty Using Coronary Accessor Trial). Reference: Satoshi Takesita, et al. Am J Cardiol 2014;113:1986-89)

Since Andreas Gruentzig performed the first angioplasty, technological development has improved devices and radial access becomes more common.  This procedure reduces complications, mainly bleeding. However, although is clinically not relevant, there is a chance of radial artery occlusion in between 3% and 10%. 

In this multicenter, randomized, prospective study, 160 patients who received angioplasty by radial access with Allen test (+), were included, 80 with 4 Fr introducer and 80 with 6 Fr. We excluded those who required secondary branch protection by kissing balloon, cutting balloon, rotational atherectomy or IVUS not compatible with 4 Fr. The Primary Endpoint was the occlusion of the radial artery a day after the procedure and secondary was the procedural success, MACE, vascular access complications, procedure time and contrast used. The characteristics of both groups were similar, the mean age was 68 years, most men and more than 70% of coronary lesions were single (A or B1). Three patients (4%) of group 6 Fr presented occlusion of the radial artery and none in the 4 Fr group (p = 0.08). There was no difference with respect to the secondary endpoint except for the shorter hemostasis and vascular complications related to access. 

Conclusion: 

The use of radial access with introducer and 4 Fr catheters can become a less invasive alternative in simple coronary angioplasty.

Editorial comment

The use of 4 Fr in coronary angioplasty marks an important advance in this technique, but can be used in non-complex procedures only, giving benefit especially to patients with thin gauge arteries and prone to spasm. Further technological development are needed in order to perform complex angioplasties using compatible devices with 4 Fr. 

Courtesy of Carlos Fava
Cardiólogo Intervencionista
Fundación Favaloro
Buenos Aires

Dr. Carlos Fava

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....